Loading
A Chinese cohort of 15,000 people at average risk followed with a multi-omic blood test for several cancers.
Jinling Cohort (NCT06011694) is an observational study sponsored by Nanjing Shihejiyin Technology, Inc. It is a prospective cohort study of the multi-omic liquid biopsy MCED test MERCURY in an average-risk Chinese population.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 15,000 participants, a start on 15 June 2022 and primary completion expected on 15 May 2027.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/